This month, U.S. companies Moderna and Pfizer launched final Phase 3 trials involving tens of thousands of volunteers. A third company, AstraZeneca, partnered with Oxford University in the United Kingdom, has already been conducting final-stage trials for weeks. And a Chinese company, CanSino Biologics, is expected to announce Phase 3 trials next month.
These developers have found promising early results, allowing them to embark upon Phase 3 clinical trials in record time.
Their success keeps opening the possibility of a vaccine being ready for wide dissemination in early 2021, although that also depends on countries having the infrastructure to administer shots to millions of people.
Anthony S. Fauci, director of the National Institute of Allergy and Infectious Disease, offered a similar analysis. On Monday, he told CNN he’s “cautiously optimistic” about the Moderna vaccine, which is being developed in collaboration with the National Institutes of Health.